NBY  Novabay Pharmaceuticals Inc.

Exchange

AMEX

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

42.78M

Vuru Grade

23.16/100

Current Price

$0.70
+0.01 (+1.45%)

Stability Price

$0.30
Overvalued by 57.83%

Company Metrics

  • 0 P/E
  • 40.01 P/S
  • 19.17 P/B
  • -0.31 EPS
  • -2,078.99% Cash ROIC
  • 1.62 Cash Ratio
  • 0 / 0% Dividend
  • 414,462.00 Avg. Vol.
  • 49.63M Shares
  • 42.78M Market Cap.

Company Description

NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Maxim Weighs in on Biotech Stocks: StemCells Inc (STEM), NovaBay ...
Smarter Analyst - May 15, 2015
Jason Kolbert of Maxim Group rates stocks in the biotechnology sector and he's ranked #2811 out of 3602 analysts on TipRanks. Yesterday, Kolbert made two news ratings for StemCells Inc (NASDAQ:STEM) and NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals (NBY) Announces Quarterly Earnings Results - WKRB News
NovaBay Announces $6.86M "At Market" Private Placement
Benzinga - May 22, 2015
"We are optimistic about NovaBay's future prospects through its ability to establish a large sales network and grow its market share in the global eye care market.
NovaBay Announces $6.86 Million “At Market” Private Placement - PharmiWeb.com (press release)
Form 8-K NovaBay Pharmaceuticals, For: May 18
StreetInsider.com - May 22, 2015
On May 18, 2015, NovaBay Pharmaceuticals, Inc. (the “Company”) entered into a definitive securities purchase agreement (the “Purchase Agreement”) with certain purchasers identified on the signature pages thereto (the “Purchasers”), pursuant to which ...
NovaBay Pharmaceuticals Inc.: NovaBay Pharmaceuticals Signs Avenova and ...
The Wall Street Transcript - Mar 9, 2015
NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products, today announced that it has signed two new distribution agreements to market its products in ...
NovaBay Pharmaceuticals Signs Avenova and NeutroPhase Distribution ... - Business Wire (press release)
NovaBay Pharmaceuticals Receives Noncompliance Notice from NYSE MKT
Yahoo Finance UK - May 1, 2015
NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY) today announced receipt of a letter from NYSE MKT LLC (“NYSE MKT” or the “Exchange”) on April 28, 2015, stating that its stockholders equity, as of December 31, 2014, is below the minimum requirements ...
Novabay Pharmaceuticals Receives New Coverage from Analysts at Maxim ... - Dakota Financial News
NovaBay Pharmaceuticals Seeks To Change The Paradigm Of Eye Care From ...
Seeking Alpha - Apr 21, 2015
NovaBay hopes Avenova will usher in a monumental change in the way that we care for our eyes that mirrors the way we care for our teeth.
NovaBay Pharmaceuticals Reports 2015 First Quarter Financial Results and ...
Business Wire (press release) - May 14, 2015
BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, today reported financial results for the three ...
NovaBay Pharma (NBY) Announces Presentation of Positive Avenova Reserach ...
StreetInsider.com - May 6, 2015
Family Eye Care Optometry and NovaBay Pharmaceuticals, Inc. (NYSE: NBY) announced that Guru Sharma O.D. Ph.D., Optometrist at Family Eye Care Optometry and Assistant Professor at Western University of the Health Sciences' College of Optometry, ...
New Laboratory Study Shows that NovaBay Pharmaceuticals' Avenova ... - Business Wire (press release)
NovaBay Pharmaceuticals Appoints Mark M. Sieczkarek Chairman
Business Wire (press release) - Apr 14, 2015
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, announces the ...
Maxim Rates NovaBay At Buy, Says 'The Eyes Have It!'
Benzinga - Apr 30, 2015
In a report published Thursday, analysts at Maxim Group initiated coverage of NovaBay Pharmaceuticals, Inc. (NYSE: NBY) with a Buy rating and a price target of $2.
NovaBay Pharmaceuticals Now Covered by Analysts at Maxim Group (NBY) - sleekmoney
Novabay Pharmaceuticals Coverage Initiated at Maxim Group (NBY) - Mideast Time